Tradestie Institutional Equity Comparison Engine
DMAC vs EDIT โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
DMAC Overall Edge
DMAC Captures Institutional Edge (3โ0 Pillars ยท 6โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to DiaMedica Therapeutics Inc. Common Stock (DMAC) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, DMAC trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus EDIT at N/M Forward P/E and -167.0% operating margin (+37.4% YoY). In options structure, DMAC sits in SURGE (14th %ile IV; Dealer Gamma Walls on Pro) against EDIT sits in BREAKDOWN (38th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
DMAC N/M vs EDIT N/M Fwd P/E
Growth & Margin Winner
DMAC
Op Margin 0.0% vs -167.0% ยท YoY +0.0% vs +37.4%
Momentum & Technical Winner
DMAC
1Y +55.3% vs -25.0% ยท 52W Pos 55% vs 11%
Options & Structure Winner
DMAC
SURGE (14th %ile IV) vs BREAKDOWN (38th %ile IV)
DMAC
NASDAQ
DiaMedica Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$8.41
-4.27% 1D
Market Cap
$503.1M
1M Return
+11.16%
1Y Return
+55.26%
Forward P/E
N/M
Unified AI Score
46.3 / 100
HOLD
Tech 30.0
Fund 51.0
Flow 65.0
Mom 60.0
EDIT
NASDAQ
Editas Medicine, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$1.91
-12.21% 1D
Market Cap
$336.5M
1M Return
-18.94%
1Y Return
-25.0%
Forward P/E
N/M
Unified AI Score
48.4 / 100
HOLD
Tech 33.0
Fund 55.0
Flow 69.0
Mom 60.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
DMAC +55.26%
EDIT -25.0%
Spread: +80.26 pp (DMAC Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | DMAC Revenue | EDIT Revenue | DMAC Op. Margin | EDIT Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $0M | $30M | -1352.2% | -356.1% | EDIT |
| FY2019 | N/A | $20M | N/A | -686.4% | EDIT |
| FY2020 | N/A | $90M | N/A | -148.6% | EDIT |
| FY2021 | N/A | $30M | N/A | -756.1% | EDIT |
| FY2022 | N/A | $20M | N/A | -1146.3% | EDIT |
| FY2023 | N/A | $80M | N/A | -216.6% | EDIT |
| FY2024 | N/A | $30M | N/A | -777.2% | EDIT |
| FY2025 | N/A | $40M | N/A | -394.9% | EDIT |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | DMAC | EDIT | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $503.1M | $336.5M | Larger Scale | DMAC |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +0.0% | +37.4% | Higher Growth | EDIT |
| Operating Margin (TTM) Profitability | 0.0% | -167.0% | Higher Margin | DMAC |
| Net Profit Margin Profitability | 0.0% | -144.9% | Higher Margin | DMAC |
| Return on Equity (ROE) Capital Efficiency | -114.6% | -147.4% | Higher ROE | DMAC |
| 52-Week Range Position Momentum | 55% ($5โ$11) | 11% ($2โ$4) | Stronger Trend | DMAC |
| Beta / 30D Volatility Risk Regime | 1.74ฮฒ ยท 98% Vol | 2.32ฮฒ ยท 102% Vol | Lower Realized Risk | DMAC |
| Unified Institutional Score Composite Signal | 46.3 / 100 (HOLD) | 48.4 / 100 (HOLD) | Higher Composite | EDIT |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full DMAC vs EDIT Buy Guide
DMAC
SURGE
8d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
14th %ile
IV Regime
Compressed (<25th %ile)
EDIT
BREAKDOWN
146d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
38th %ile
IV Regime
Balanced (25thโ60th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither DMAC nor EDIT registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.